Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
Women of all ages will get round-the-clock access to comprehensive treatment
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
Various healthcare companies are already implementing high-tech solutions into existing healthcare systems.
Subgroup analysis by HER2 expression from phase 1/2 trial of patients with HER3 expressing metastatic breast cancer highlighted in a second Presidential Session
New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics and other self-administered therapies
A funding to expand operations and provide better patient care
Chronic Kidney Disease is a growing epidemic with 850 million people affected worldwide.
Time to combine innovation, access and technology to deliver positive patient outcomes
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
Subscribe To Our Newsletter & Stay Updated
